Drug strategies for the treatment and prevention of proliferative vitreoretinopathy: an overview of innovative treatment concepts.

Int Ophthalmol · 2026 · PMC12860817 · PMID 41619046

Europe PMC DOI

hedged sentence

0.0420

closest p · 0.8× alpha

0.0420

boldest claim

The sentences

did not reach statistical significancep = 0.042actually significant

33%) did not reach statistical significance, the treatment group showed later onset of recurrence (9.5 vs. 2.9 weeks, p = 0.042), a lower rate of advanced PVR ( p = 0.038), and significantly better final visual acuity outcomes ( p = 0.035) [ 51 ].

also in 53,799 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.